A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Conditions

• Acute Heart Failure
• Heart Failure

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Finerenone — DRUG
  Oral finerenone
• Placebo — DRUG
  Matching oral placebo

Study Details

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Key Dates

Start date

Jan 17, 2024

Status verified

May 2026

Primary completion

Nov 30, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

5,200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Finerenone
• Placebo Comparator: Placebo

Primary Outcome Measure

Composite of total HF events and cardiovascular (CV) death. [ Time Frame: Ongoing, up to ~30 months ]

Central Contacts

• Marc Bonaca
  303-860-9900
  [email protected]

Locations (77)

Find similar trials in Birmingham, AL

Related Studies

• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  Recruiting · Medtronic · Birmingham, Alabama
• Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
  Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
• Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
  Recruiting · Arunark Kolipaka · Columbus, Ohio
• Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
  Recruiting · University of Florida · Gainesville, Florida